Assessment of symptomatic women for early diagnosis of ovarian cancer: Results from the prospective DOvE pilot project

The Lancet Oncology

Volumn 13, Issue 3, 2012, Pages 285-291

  Gilbert, Lucy ^a   Basso, Olga ^a   Sampalis, John ^a,b   Karp, Igor ^c,d   Martins, Claudia ^a   Feng, Jing ^a   Piedimonte, Sabrina ^a   Quintal, Louise ^a   Ramanakumar, Agnihotram V ^a   Takefman, Janet ^a   Grigorie, Maria S ^a   Artho, Giovanni ^a   Krishnamurthy, Srinivasan ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANADA; CANCER GRADING; CANCER INVASION; CANCER SCREENING; CANCER SURGERY; CONTROLLED STUDY; DEMOGRAPHY; EARLY CANCER; EARLY DIAGNOSIS; EDUCATIONAL STATUS; FEMALE; GYNECOLOGIC CANCER; HIGH RISK PATIENT; HUMAN; LANGUAGE; MAJOR CLINICAL STUDY; OVARY CANCER; PILOT STUDY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; SYMPTOM; TRANSVAGINAL ECHOGRAPHY;

AGED; ALGORITHMS; CA-125 ANTIGEN; CHI-SQUARE DISTRIBUTION; EARLY DETECTION OF CANCER; FEASIBILITY STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MASS SCREENING; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; PROSPECTIVE STUDIES; QUEBEC; TUMOR BURDEN;

EID: 84857508226     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(11)70333-3     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, Ward E Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Huang L, Cronin KA, Johnson KA, Mariotto AB, Feuer EJ Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer?. Cancer 2008, 112:2289-2300.
3. Cho KR, Shih IeM Ovarian cancer. Annu Rev Pathol 2009, 4:287-313.
4. Seidman JD, Zhao P, Yemelyanova A "Primary peritoneal" high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol Oncol 2011, 120:470-473.
5. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002, 20:1248-1259.
6. Chi DS, Eisenhauer EL, Lang J, et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol Oncol 2006, 103:559-564.
7. US Preventive Services Task Force. Screening for ovarian cancer: recommendation statement. (accessed Nov 29, 2011). http://www.uspreventiveservicestaskforce.org/uspstf/uspsovar.htm.
8. Kobayashi H, Yamada Y, Sado T, et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer 2008, 18:414-420.
9. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009, 10:327-340.
10. Buys SS, Partridge E, Greene MH, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol 2005, 193:1630-1639.
11. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011, 305:2295-2303.
12. Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007, 109:221-227.
13. Goff BA, Mandel LS, Melancon CH, Muntz HG Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004, 291:2705-2712.
14. Bankhead CR, Kehoe ST, Austoker J Symptoms associated with diagnosis of ovarian cancer: a systematic review. BJOG 2005, 112:857-865.
15. Hamilton W, Peters TJ, Bankhead C, Sharp D Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. BMJ 2009, 339:b2998.
16. Bankhead CR, Collins C, Stokes-Lampard H, et al. Identifying symptoms of ovarian cancer: a qualitative and quantitative study. BJOG 2008, 115:1008-1014.
17. Smith LH, Morris CR, Yasmeen S, Parikh-Patel A, Cress RD, Romano PS Ovarian cancer: can we make the clinical diagnosis earlier?. Cancer 2005, 104:1398-1407.
18. Fitch M, Deane K, Howell D, Gray RE Women's experiences with ovarian cancer: reflections on being diagnosed. Can Oncol Nurs J 2002, 12:152-168.
19. Goff BA, Mandel L, Muntz HG, Melancon CH Ovarian carcinoma diagnosis. Cancer 2000, 89:2068-2075.
20. National Cancer Institute. Groups say common symptoms may indicate ovarian cancer. (accessed Nov 28, 2011). http://www.cancer.gov/aboutnci/ncicancerbulletin/archive/2007/062607/page4.
21. Burger RA A new model of ovarian carcinogenesis may influence early detection strategies. Am J Obstet Gynecol 2008, 198:349-350.
22. Morgan RJ, Alvarez RD, Armstrong DK, et al. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: epithelial ovarian cancer. J Natl Compr Canc Netw 2011, 9:82-113.
23. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990, 97:922-929.
24. Vorgias G, Iavazzo C, Savvopoulos P, et al. Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study. Gynecol Oncol 2009, 112:11-15.
25. Chi DS, Zivanovic O, Palayekar MJ, et al. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol Oncol 2009, 112:6-10.
26. Kurman RJ, Shih IeM The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010, 34:433-443.
27. Crum CP Intercepting pelvic cancer in the distal fallopian tube: theories and realities. Mol Oncol 2009, 3:165-170.
28. Hoskins WJ, McGuire WP, Brady MF, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994, 170:974-979. discussion 979-80.
29. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009, 115:1234-1244.
30. Zhu CS, Pinsky PF, Cramer DW, et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) 2011, 4:375-383.
31. Rufford BD, Jacobs IJ, Menon U Feasibility of screening for ovarian cancer using symptoms as selection criteria. BJOG 2007, 114:59-64.
32. Barrett J, Sharp DJ, Stapley S, Stabb C, Hamilton W Pathways to the diagnosis of ovarian cancer in the UK: a cohort study in primary care. BJOG 2010, 117:610-614.
33. Jelovac D, Armstrong DK Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011, 61:183-203.